Search

Your search keyword '"Grieken, N.C.T. van"' showing total 20 results
Start Over Author "Grieken, N.C.T. van"
20 results on '"Grieken, N.C.T. van"'

1. The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer.

Author

Doeve, B.H., Bakx, J.A.C., Siersema, P.D., Rosman, C., Grieken, N.C.T. van, Berge Henegouwen, M.I. van, Sandick, J.W. van, Verheij, M., Bijlsma, M.F., Verhoeven, R.H.A., Laarhoven, H.W. van, Doeve, B.H., Bakx, J.A.C., Siersema, P.D., Rosman, C., Grieken, N.C.T. van, Berge Henegouwen, M.I. van, Sandick, J.W. van, Verheij, M., Bijlsma, M.F., Verhoeven, R.H.A., and Laarhoven, H.W. van

Abstract

Item does not contain fulltext, BACKGROUND: The COVID-19 pandemic has affected the entire global healthcare system, including oncological care. This study investigated the effects of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer in the Netherlands. METHODS: Patients diagnosed in 2020 were divided into 5 periods, based on the severity of the COVID-19 pandemic in the Netherlands, and compared to patients diagnosed in the same period in the years 2017-2019. Patient characteristics and treatments were evaluated for esophageal cancer (EC) and gastric cancer (GC) separately. RESULTS: The number of esophagogastric cancer diagnoses decreased prominently during the first 2 months of the COVID-19 pandemic. During this period, a significantly higher percentage of GC patients was diagnosed with incurable disease (52.5% in 2017-2019 and 67.7% in 2020, p = 0.011). We observed a significant reduction in the percentage of patients with potentially curable EC treated with resection and neoadjuvant chemoradiotherapy (from 35.0% in 2017-2019 to 27.3% in 2020, p < 0.001). Also, patients diagnosed with incurable GC were treated less frequently with a resection (from 4.6% in 2017-2019 to 1.5% in 2020, p = 0.009) in the second half of 2020. CONCLUSIONS: Compared to previous years, the number of esophagogastric cancer diagnoses decreased in the first 2 months of the COVID-19 pandemic, while an increased percentage of patients was diagnosed with incurable disease. Both in the curative and palliative setting, patients were less likely to be treated with a surgical resection.

Published
2023

2. Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial

Author

Slagter, A.E., Vollebergh, M.A., Caspers, I.A., Sandick, J.W. van, Sikorska, K., Lind, P., Nordsmark, M., Putter, H., Braak, J., Meershoek-Klein Kranenbarg, E., Velde, C.J. van de, Jansen, E.P.M., Cats, A., Laarhoven, H.W.M. van, Grieken, N.C.T. van, Verheij, M., Slagter, A.E., Vollebergh, M.A., Caspers, I.A., Sandick, J.W. van, Sikorska, K., Lind, P., Nordsmark, M., Putter, H., Braak, J., Meershoek-Klein Kranenbarg, E., Velde, C.J. van de, Jansen, E.P.M., Cats, A., Laarhoven, H.W.M. van, Grieken, N.C.T. van, and Verheij, M.

Abstract

Item does not contain fulltext, AIM: To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer. METHODS: We performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses. Likelihoods to receive potentially curative surgery were investigated for patients without elevated tumor markers versus one of the tumor markers elevated versus both tumor markers elevated. The association between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 patients with available ctDNA data. RESULTS: In multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11-1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42-2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters. CONCLUSION: CEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.

Published
2022

4. Diagnostic variability in the histopathological assessment of advanced colorectal adenomas and early colorectal cancer in a screening population

Author

Smits, L.J.M, Vink-Borger, Elisa, Lijnschoten, G. van, Focke-Snieders, I., Post, R.S. van der, Tuynman, J.B., Grieken, N.C.T. van, Nagtegaal, I.D., Smits, L.J.M, Vink-Borger, Elisa, Lijnschoten, G. van, Focke-Snieders, I., Post, R.S. van der, Tuynman, J.B., Grieken, N.C.T. van, and Nagtegaal, I.D.

Abstract

Item does not contain fulltext, AIM: The aim of this study was to evaluate interobserver variability between individual pathologists and a panel of pathologists in the histopathological assessment of advanced colorectal neoplasms in the Dutch bowel cancer screening population. METHODS AND RESULTS: Histological slides of adenomas with high-grade dysplasia and early colorectal carcinomas (CRC) from 20 different laboratories were reviewed by the pathology panel of the Dutch bowel screening programme. Interobserver variability was reported by descriptive statistics. In addition, potential clinical consequences of discrepancies were evaluated. A total of 104 cases of adenomas with high-grade dysplasia and 83 early CRCs were reviewed. Discrepancies were observed in 41 of 104 (39.4%) adenoma cases, which potentially had clinical consequences in 16 (15.4%) cases. For CRC, discrepancies were shown in 44 of 83 cases (53.0%) and would have potentially led to alternative treatment strategies in 25 (30.1%) cases. Most frequently, discrepancies were observed in the assessment of lymphovascular invasion (23 of 73 cases, 31.5%). CONCLUSION: This study showed that considerable interobserver variability is present in the histopathological assessment of advanced colorectal neoplasia, which may impact upon treatment choices. Additional stains and education, as well as intercollegial consultation, might decrease this variability.

Published
2022

5. Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.

Author

Biesma, H.D., Soeratram, T.T.D., Sikorska, K., Caspers, I.A., Essen, H.F. van, Egthuijsen, J.M.P., Mookhoek, A., Laarhoven, H.W.M. van, Berge Henegouwen, M.I. van, Nordsmark, M., Peet, D.L. van der, Warmerdam, F., Geenen, M.M., Loosveld, O.J., Portielje, J.E., Los, M., Heideman, D.A.M., Meershoek-Klein Kranenbarg, E., Hartgrink, H.H., Sandick, J. van, Verheij, M., Velde, C.J. van de, Cats, A., Ylstra, B., Grieken, N.C.T. van, Biesma, H.D., Soeratram, T.T.D., Sikorska, K., Caspers, I.A., Essen, H.F. van, Egthuijsen, J.M.P., Mookhoek, A., Laarhoven, H.W.M. van, Berge Henegouwen, M.I. van, Nordsmark, M., Peet, D.L. van der, Warmerdam, F., Geenen, M.M., Loosveld, O.J., Portielje, J.E., Los, M., Heideman, D.A.M., Meershoek-Klein Kranenbarg, E., Hartgrink, H.H., Sandick, J. van, Verheij, M., Velde, C.J. van de, Cats, A., Ylstra, B., and Grieken, N.C.T. van

Abstract

Item does not contain fulltext

Published
2022

6. Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer

Author

Slagter, A.E., Caspers, I.A., Grieken, N.C.T. van, Walraven, I., Lind, P., Meershoek-Klein Kranenbarg, E., Grootscholten, C, Nordsmark, M., Sandick, J.W. van, Sikorska, K., Velde, C.J. van de, Jansen, E.P.M., Verheij, M., Laarhoven, H.W.M. van, Cats, A., Slagter, A.E., Caspers, I.A., Grieken, N.C.T. van, Walraven, I., Lind, P., Meershoek-Klein Kranenbarg, E., Grootscholten, C, Nordsmark, M., Sandick, J.W. van, Sikorska, K., Velde, C.J. van de, Jansen, E.P.M., Verheij, M., Laarhoven, H.W.M. van, and Cats, A.

Abstract

Contains fulltext : 251455.pdf (Publisher’s version ) (Open Access), (1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the curative setting as well. However, evidence to prefer oxaliplatin over cisplatin in the curative setting is limited. (2) Methods: We compared patient-related and tumor-related outcomes for cisplatin versus oxaliplatin in patients with resectable gastric cancer treated with perioperative chemotherapy in the CRITICS trial. (3) Results: Preoperatively, 632 patients received cisplatin and 149 patients received oxaliplatin. Preoperative severe toxicity was encountered in 422 (67%) patients who received cisplatin versus 89 (60%) patients who received oxaliplatin (p = 0.105). Severe neuropathy was observed in 5 (1%) versus 6 (4%; p = 0.009) patients, respectively. Postoperative severe toxicity occurred in 109 (60%) versus 26 (51%) (p = 0.266) patients; severe neuropathy in 2 (1%) versus 2 (4%; p = 0.209) for patients who received cisplatin or oxaliplatin, respectively. Diarrhea impacted the quality of life more frequently in patients who received oxaliplatin compared to cisplatin. Complete or near-complete pathological response was achieved in 94 (21%) versus 16 (15%; p = 0.126) patients who received cisplatin or oxaliplatin, respectively. Overall survival was not significantly different in both groups (p = 0.300). (4) Conclusions: Both cisplatin and oxaliplatin are legitimate options as part of systemic treatment in patients with resectable gastric cancer.

Published
2022

7. Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts

Author

Quaas, A., Biesma, H.D., Wagner, A.D., Verheij, M., Berge Henegouwen, M.I. van, Schoemig-Markiefka, B., Pamuk, A., Zander, T., Siemanowski, J., Sikorska, K., Egthuijsen, J.M.P., Meershoek-Klein Kranenbarg, E.M., Velde, C.J. van de, Buettner, R., Alakus, H., Cats, A., Ylstra, B., Laarhoven, H.W. van, Grieken, N.C.T. van, Quaas, A., Biesma, H.D., Wagner, A.D., Verheij, M., Berge Henegouwen, M.I. van, Schoemig-Markiefka, B., Pamuk, A., Zander, T., Siemanowski, J., Sikorska, K., Egthuijsen, J.M.P., Meershoek-Klein Kranenbarg, E.M., Velde, C.J. van de, Buettner, R., Alakus, H., Cats, A., Ylstra, B., Laarhoven, H.W. van, and Grieken, N.C.T. van

Abstract

Contains fulltext : 283432.pdf (Publisher’s version ) (Open Access), OBJECTIVE: Biological sex differences in cancer are increasingly acknowledged. Here, we examined these differences in clinicopathological characteristics and survival in microsatellite instability (MSI)-high and microsatellite stable (MSS) gastric cancer (GC). DESIGN: We analysed MSI status by polymerase chain reaction (PCR) and/or mismatch repair (MMR) status by immunohistochemistry in a pooled analysis of individual patient data from one retrospective cohort from Cologne, and the randomised phase III clinical trials D1/D2 and CRITICS. All patients had resectable adenocarcinoma of the stomach and/or gastro-oesophageal junction. Patients were treated with either surgery only or perioperative chemo(radio)therapy. RESULTS: MSI and/or MMR analyses on 1307 tumours resulted in 1192 (91.2%) MSS and/or MMR proficient (MMRP) [median age, 65 years; 759 males (63.7%); 619 treated with surgery only (51.9%)], and 115 (8.8%) MSI-high [median age, 69 years; 67 males (58.3%); 76 treated with surgery only (66.1%)] GC cases. Males had shorter overall survival (OS) than female MSI-high GC (5-year OS 34.7% vs. 69.7%; hazard ratio (HR) 2.68, 95%CI 1.60 to 4.49; p < 0.001). Females with MSI-high had longer OS than those with MSS/MMRP GC (HR 0.61, 95%CI 0.41 to 0.92; p = 0.02). Males with MSI-high did not have longer OS than those with MSS/MMRP GC (HR 1.26, 95%CI 0.94 to 1.69; p = 0.12). CONCLUSIONS: MSI-high GC males had a significantly worse prognosis compared to their female counterparts in three independent cohorts. In addition, the favourable prognostic value of MSI was only seen in females and not in males. These observations emphasise the need to consider sex differences in prognosis and treatment effects in oncology. CLINICAL TRIAL REGISTRATION: The CRITICS trial is registered at ClinicalTrials.gov, number NCT00407186; EudraCT, number 2006-004130-32; and CKTO, 2006-02.

Published
2022

9. IBD-associated dysplastic lesions show more chromosomal instability than sporadic adenomas

Author

Wanders, L.K., Cordes, M., Voorham, Q., Sie, D., Vries, S.D. de, d'Haens, G.R.A.M., Boer, N.K.H. de, Ylstra, B., Grieken, N.C.T. van, Meijer, G.A., Dekker, E., and Carvalho, B.

Abstract

Inflammatory bowel disease (IBD) patients are at increased risk of developing colorectal cancer. However, histologically, it is challenging to distinguish between IBD-associated dysplasia from sporadic adenomas. We have molecularly characterized these precursor lesions and show that IBD-associated dysplasia lesions are genomically much more unstable.

Published
2020

10. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC)

Author

Gertsen, E.C., Brenkman, H.J.F., Hillegersberg, R. van, Sandick, J.W. van, Berge Henegouwen, M.I. van, Gisbertz, S.S., Luyer, M.D., Nieuwenhuijzen, G.A., Lanschot, J.Jan B. van, Lagarde, S.M., Wijnhoven, B.P., Steur, W.O. de, Hartgrink, H.H., Stoot, J., Hulsewe, K.W., Bilgen, E.J., Det, M.J. van, Kouwenhoven, E.A., Peet, D.L. van der, Daams, F., Grieken, N.C.T. van, Heisterkamp, J., Etten, B. van, Berg, J.W.K. van den, Pierie, J.P.E.N., Eker, H.H., Thijssen, A.Y., Belt, E.J., Duijvendijk, P. van, Wassenaar, E., Laarhoven, H.W. van, Wevers, K.P., Hol, L., Wessels, F.J., Mohammad, N. Haj, Meulen, M.P. van der, Frederix, G.W., Vegt, E, Siersema, P.D., Ruurda, J.P., Gertsen, E.C., Brenkman, H.J.F., Hillegersberg, R. van, Sandick, J.W. van, Berge Henegouwen, M.I. van, Gisbertz, S.S., Luyer, M.D., Nieuwenhuijzen, G.A., Lanschot, J.Jan B. van, Lagarde, S.M., Wijnhoven, B.P., Steur, W.O. de, Hartgrink, H.H., Stoot, J., Hulsewe, K.W., Bilgen, E.J., Det, M.J. van, Kouwenhoven, E.A., Peet, D.L. van der, Daams, F., Grieken, N.C.T. van, Heisterkamp, J., Etten, B. van, Berg, J.W.K. van den, Pierie, J.P.E.N., Eker, H.H., Thijssen, A.Y., Belt, E.J., Duijvendijk, P. van, Wassenaar, E., Laarhoven, H.W. van, Wevers, K.P., Hol, L., Wessels, F.J., Mohammad, N. Haj, Meulen, M.P. van der, Frederix, G.W., Vegt, E, Siersema, P.D., and Ruurda, J.P.

Abstract

Item does not contain fulltext, IMPORTANCE: The optimal staging for gastric cancer remains a matter of debate. OBJECTIVE: To evaluate the value of 18F-fludeoxyglucose-positron emission tomography with computed tomography (FDG-PET/CT) and staging laparoscopy (SL) in addition to initial staging by means of gastroscopy and CT in patients with locally advanced gastric cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective, observational cohort study included 394 patients with locally advanced, clinically curable gastric adenocarcinoma (≥cT3 and/or N+, M0 category based on CT) between August 1, 2017, and February 1, 2020. EXPOSURES: All patients underwent an FDG-PET/CT and/or SL in addition to initial staging. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of patients in whom the intent of treatment changed based on the results of these 2 investigations. Secondary outcomes included diagnostic performance, number of incidental findings on FDG-PET/CT, morbidity and mortality after SL, and diagnostic delay. RESULTS: Of the 394 patients included, 256 (65%) were men and mean (SD) age was 67.6 (10.7) years. A total of 382 patients underwent FDG-PET/CT and 357 underwent SL. Treatment intent changed from curative to palliative in 65 patients (16%) based on the additional FDG-PET/CT and SL findings. FDG-PET/CT detected distant metastases in 12 patients (3%), and SL detected peritoneal or locally nonresectable disease in 73 patients (19%), with an overlap of 7 patients (2%). FDG-PET/CT had a sensitivity of 33% (95% CI, 17%-53%) and specificity of 97% (95% CI, 94%-99%) in detecting distant metastases. Secondary findings on FDG/PET were found in 83 of 382 patients (22%), which led to additional examinations in 65 of 394 patients (16%). Staging laparoscopy resulted in a complication requiring reintervention in 3 patients (0.8%) without postoperative mortality. The mean (SD) diagnostic delay was 19 (14) days. CONCLUSIONS AND RELEVANCE: This study's findings suggest an apparently limi

Published
2021

12. Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial

Author

Caspers, Irene A., Sikorska, Karolina, Slagter, Astrid E., Amelsfoort, Romy M. van, Kranenbarg, Elma Meershoek-Klein, Velde, Cornelis J.H. van de, Verheij, M., Cats, A., Grieken, N.C.T. van, Caspers, Irene A., Sikorska, Karolina, Slagter, Astrid E., Amelsfoort, Romy M. van, Kranenbarg, Elma Meershoek-Klein, Velde, Cornelis J.H. van de, Verheij, M., Cats, A., and Grieken, N.C.T. van

Abstract

Contains fulltext : 238461.pdf (Publisher’s version ) (Open Access)

Published
2021

14. Increased apoptosis in gastric mucosa adjacent to intestinal metaplasia. (Original Article)

Author

Grieken, N.C.T. van, Meijer, G.A., Hausen, A. zur, Meuwissen, S.G.M., Baak, J.P.A., and Kuipers, E.J.

Subjects
Research, Apoptosis -- Research, Research methods -- Research, Metaplasia -- Research, Methodology -- Research
Abstract

Background: The biological processes involved in the development of gastric mucosal atrophy and intestinal metaplasia are still incompletely understood. Reports testing the hypothesis that apoptosis leads to atrophy have yielded [...]

Published
2003

15. Nationwide comprehensive gastro-intestinal cancer cohorts

Author

Braak, R.R.J.C. van den, Rijssen, L.B. van, Kleef, J.J. van, Vink, G.R., Berbee, M., Henegouwen, M.I.V., Bloemendal, H.J., Bruno, M.J., Burgmans, M.C., Busch, O.R.C., Coene, P.P.L.O., Coupe, V.M.H., Dekker, J.W.T., Eijck, C.H.J. van, Elferink, M.A.G., Erdkamp, F.L.G., Grevenstein, W.M.U. van, Groot, J.W.B. de, Grieken, N.C.T. van, Hingh, I.H.J.T. de, Hulshof, M.C.C.M., Ijzermans, J.N.M., Kwakkenbos, L., Lemmens, V.E.P.P., M. los, Meijer, G.A., Molenaar, I.Q., Nieuwenhuijzen, G.A.P., Noo, M.E. de, Poll-Franse, L.V. van de, Punt, C.J.A., Rietbroek, R.C., Roeloffzen, W.W.H., Rozema, T., Ruurda, J.P., Sandick, J.W. van, Schiphorst, A.H.W., Schipper, H., Siersema, P.D., Slingerland, M., Sommeijer, D.W., Spaander, M.C.W., Sprangers, M.A.G., Stockmann, H.B.A.C., Strijker, M., Tienhoven, G. van, Timmermans, L.M., Tjin-a-Ton, M.L.R., Velden, A.M.T. van der, Verhaar, M.J., Verkooijen, H.M., Vles, W.J., Vos-Geelen, J.M.P.G.M. de, Wilmink, J.W., Zimmerman, D.D.E., Oijen, M.G.H. van, Koopman, M., Besselink, M.G.H., Laarhoven, H.W.M. van, Dutch Pancreatic Canc Grp, Dutch Upper GI Canc Grp, PLCRC Working Grp, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, Promovendi ODB, MUMC+: MA Radiotherapie OC (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), CCA - Cancer Treatment and quality of life, APH - Methodology, Epidemiology and Data Science, AGEM - Re-generation and cancer of the digestive system, Pathology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, Surgery, Graduate School, Radiotherapy, Oncology, APH - Aging & Later Life, APH - Mental Health, Medical Psychology, APH - Quality of Care, Gastroenterology & Hepatology, Public Health, Erasmus MC other, and Medical and Clinical Psychology

Subjects
0301 basic medicine, medicine.medical_specialty, INFRASTRUCTURE, law.invention, COLORECTAL-CANCER, Cohort Studies, Experimental Psychopathology and Treatment, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Randomized controlled trial, SDG 3 - Good Health and Well-being, DESIGN, law, Informed consent, MOLECULAR SUBTYPES, medicine, Humans, QUALITY, Radiology, Nuclear Medicine and imaging, Registries, Biological Specimen Banks, Gastrointestinal Neoplasms, Randomized Controlled Trials as Topic, ESOPHAGEAL, INFORMED-CONSENT, business.industry, Clinical study design, Cancer, Hematology, General Medicine, medicine.disease, Surgery, Cancer registry, Clinical trial, Observational Studies as Topic, 030104 developmental biology, Oncology, Research Design, 030220 oncology & carcinogenesis, Cohort, Emergency medicine, business, CLINICAL-TRIALS, Cohort study
Abstract

Contains fulltext : 190038.pdf (Publisher’s version ) (Open Access) Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients.Material and methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future.Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing.Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting. 8 p.

Published
2018
Full Text
View/download PDF

16. Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab

Author

Dijk, E. van, Biesma, H., Cordes, M., Smeets, D., Neerincx, M., S. das, Murphy, V., Barat, A., Bacon, O., Prehn, J.H.M., Betge, J., Timo, G., Fender, B., Meijer, G.A., McNamara, D.A., Klinger, R., Koopman, M., Ebert, M.P.A., Kay, E.W., Hennessey, B.T., Verheul, H.M.W., Gallagher, W.M., O'Connor, D.P., Punt, C.J.A., Loupakis, F., Lambrechts, D., Byrne, A., Grieken, N.C.T. van, and Ylstra, B.

Published
2018
Full Text
View/download PDF

17. Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer

Author

Amelsfoort, R. van, Walraven, I., Jansen, E.P.M., Cats, A., Grieken, N.C.T. van, Aaronson, N.K., Boot, H., Lind, P.A., Kranenbarg, E.M.K., Nordsmark, M., Putter, H., Trip, A.K., Sandick, J.W. van, Sikorska, K., Tinteren, H. van, Velde, C.J.H. van de, and Verheij, M.

Published
2018

19. Rapid quantitative assessment of gastric corpus atrophy in tissue sections

Author

Grieken, N.C.T. van, Weiss, M.M., Meijer, G.A., Bloemena, E., Lindeman, J., Offerhaus, G.J.A., Meuwissen, S.G.M., Baak, J.P.A., and Kuipers, E.J.

Abstract

Background/Aims--Grading of Helicobacter pylori induced atrophic gastritis using the updated Sydney system is severely limited by high interobserver variability. The aim of this study was to set up a quantitative test of gastric corpus mucosal atrophy in tissue sections and test its reproducibility and correlation with the Sydney scores of atrophy. Method--Mucosal atrophy was assessed in 124 haematoxylin and eosin stained corpus biopsy specimens by two experienced gastrointestinal pathologists (EB, JL) according to the updated Sydney system as none (n = 33), mild (n = 33), moderate (n = 33), or pronounced (n = 25). In each specimen, the proportions of glands, stroma, infiltrate, and intestinal metaplasia in the glandular zone were measured as volume percentages using a point counting method. The optimal point sample size, intra-observer and interobserver reproducibility, discriminative power for degrees of atrophy, and correlations with H pylori status were evaluated. Results--Counting 400 points in 200 fields of vision provided the smallest sample size that still had excellent intra-observer and interobserver reproducibility (r ≥ 0.96). Overall, the volume percentage of glands (VPGL), infiltrate (VPI), and stroma (VPS) correlated well with the Sydney scores for atrophy (p ≤ 0.003). However, no differences were found between non-atrophic mucosa and mild atrophy. No correlation was found between age and either the Sydney grade of atrophy or the VPGL or VPS. In non-atrophic mucosa and mild atrophy, H pylori positive cases showed a significantly higher VPI than did H pylori negative cases. A lower VPGL was seen in H pylori positive cases than in H pylori negative cases in the mild atrophy group. VPS did not correlate with H pylori status within each grade of atrophy. Conclusion--Point counting is a powerful and reproducible tool for the quantitative analysis of mucosal corpus atrophy in tissue sections. These data favour the combination of "none" and "mild" atrophy into one category, resulting in a three class grading system for corpus atrophy, when using the updated Sydney system.

Published
2001

20. Comparative genomic hybridisation

Author

Weiss, M.M., Grieken, N.C.T. van, Kuipers, E.J., Hermsen, M.A.J.A., Meijer, G.A., Baak, J.P.A., and Diest, P.J. van

Abstract

Comparative genomic hybridisation (CGH) is a technique that permits the detection of chromosomal copy number changes without the need for cell culturing. It provides a global overview of chromosomal gains and losses throughout the whole genome of a tumour. Tumour DNA is labelled with a green fluorochrome, which is subsequently mixed (1:1) with red labelled normal DNA and hybridised to normal human metaphase preparations. The green and red labelled DNA fragments compete for hybridisation to their locus of origin on the chromosomes. The green to red fluorescence ratio measured along the chromosomal axis represents loss or gain of genetic material in the tumour at that specific locus. In addition to a fluorescence microscope, the technique requires a computer with dedicated image analysis software to perform the analysis. This review aims to provide a detailed discussion of the CGH technique, and to provide a protocol with an emphasis on crucial steps.

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results